BIOCRYST PHARMACEUTICALS, INC. Available-for-sale Securities, Amortized Cost Basis
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Available-for-sale Securities, Amortized Cost Basis of $105.24 million as of 2017-12-31, per its 10-K filed 2018-03-12.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-03-12
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $105.24M.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $48.23M.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $50.45M.
- 2017-03-31: Available-for-sale Securities, Amortized Cost Basis $27.26M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2017-12-31 | $105.24M 10-K · filed 2018-03-12 |
| 2017-09-30 | $48.23M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $50.45M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $27.26M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $41.41M 10-K · filed 2018-03-12 |
| 2016-09-30 | $31.71M 10-Q · filed 2016-11-08 |
| 2016-06-30 | $50.98M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $63.82M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $70.26M 10-K · filed 2017-02-27 |
| 2015-09-30 | $71.28M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $53.51M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $60.07M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $59.30M 10-K · filed 2016-02-26 |
| 2014-09-30 | $6.28M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $11.17M 10-Q · filed 2014-08-08 |
| 2014-03-31 | $20.44M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $19.42M 10-K · filed 2015-03-02 |
| 2013-09-30 | $17.16M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $9.32M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $13.39M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $15.78M 10-K · filed 2014-03-10 |
| 2012-09-30 | $19.43M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $29.18M 10-Q · filed 2012-08-08 |
| 2011-12-31 | $40.45M 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |